Immunome, Inc. (NASDAQ:IMNM) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Immunome, Inc. (NASDAQ:IMNM) has received an average recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $34.25.

A number of equities research analysts recently weighed in on the stock. Stifel Nicolaus initiated coverage on shares of Immunome in a research note on Wednesday, September 30th. They set a “hold” rating and a $24.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Immunome in a report on Thursday, September 10th. Truist Financial increased their target price on shares of Immunome from $37.00 to $38.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Citigroup reiterated a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a research note on Friday, July 17th.

Insider Transactions at Immunome

In other news, insider Kinney Horn sold 90,616 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $25.09, for a total value of $2,273,555.44. Following the completion of the sale, the insider directly owned 50,366 shares of the company’s stock, valued at approximately $1,263,682.94. This represents a 64.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jack Higgins sold 13,200 shares of the stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $25.32, for a total transaction of $334,224.00. Following the completion of the transaction, the insider owned 65,050 shares of the company’s stock, valued at $1,647,066. This trade represents a 16.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 223,368 shares of company stock valued at $5,747,142. Company insiders own 7.21% of the company’s stock.

Institutional Investors Weigh In On Immunome

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Allworth Financial LP acquired a new position in shares of Immunome in the 2nd quarter valued at $25,000. Integrated Wealth Concepts LLC purchased a new position in Immunome in the 2nd quarter worth about $27,000. KBC Group NV purchased a new position in Immunome in the 1st quarter worth about $60,000. GK Wealth Management LLC acquired a new stake in Immunome during the 3rd quarter worth about $71,000. Finally, Assetmark Inc. raised its holdings in Immunome by 46.6% during the 1st quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock worth $99,000 after buying an additional 1,442 shares during the period. Institutional investors own 44.58% of the company’s stock.

Immunome Price Performance

Shares of Immunome stock opened at $19.55 on Wednesday. The business’s fifty day moving average price is $25.02 and its two-hundred day moving average price is $22.84. The company has a market capitalization of $2.22 billion, a P/E ratio of -7.73 and a beta of 2.55. Immunome has a 1-year low of $13.49 and a 1-year high of $30.06.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). On average, research analysts expect that Immunome will post -2.51 earnings per share for the current fiscal year.

About Immunome

Immunome, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapeutics for cancer and immune-related diseases. The company uses its antibody discovery and development capabilities to identify potentially differentiated treatments designed to address significant unmet medical needs.

Immunome’s research activities are centered on building a pipeline of monoclonal antibody programs, including candidates directed at targets relevant to oncology and inflammatory or immune-mediated conditions.